Literature DB >> 1322559

Effect of piperacillin/tazobactam therapy on intestinal microflora.

C E Nord1, B Brismar, B Kasholm-Tengve, G Tunevall.   

Abstract

The effect of piperacillin/tazobactam treatment upon the intestinal microflora was studied in 20 patients with intraabdominal infections. The patients received piperacillin 4 g combined with tazobactam 500 mg q 8 h by intravenous injection for 4-8 days. Stool specimens were collected before, during and after therapy for cultivation of aerobic and anaerobic microorganisms. Six patients had measurable concentrations of piperacillin (1.2-276 mg/kg/faeces) and 4 patients tazobactam concentrations (0.8-22.2 mg/kg/faeces) in the faecal specimens during therapy. The number of enterobacteria and enterococci slightly decreased while there were no changes in the number of staphylococci and bacilli. The anaerobic microflora was also slightly affected. There was a minor decrease in the number of bifidobacteria, eubacteria, lactobacilli, clostridia and veillonella but the numbers of anaerobic Gram-positive cocci and bacteroides were not influenced by the treatment. After therapy, the aerobic and anaerobic microflora returned to normal levels in all patients. None of the patients had Clostridium difficile or cytotoxin in the stools or developed diarrhoea.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322559     DOI: 10.3109/00365549209052614

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

2.  High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous β-Lactams.

Authors:  Eva M González-Barberá; Jaime Sanz; Ana Djukovic; Alejandro Artacho; Iván Peñaranda; Beatriz Herrera; María José Garzón; Miguel Salavert; José Luis López-Hontangas; Karina B Xavier; Bernhard Kuster; Laurent Debrauwer; Jean-Marc Rolain; Miguel A Sanz; Joao B Xavier; Carles Ubeda
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

Review 3.  The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.

Authors:  C E Nord
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

4.  Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.

Authors:  David L Paterson; Carlene A Muto; Magdaline Ndirangu; Peter K Linden; Brian A Potoski; Blair Capitano; Robert A Bonomo; David C Aron; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2007-11-19       Impact factor: 5.191

Review 5.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

6.  Effects of treatment with antimicrobial agents on the human colonic microflora.

Authors:  Fatemeh Rafii; John B Sutherland; Carl E Cerniglia
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

7.  The use of first-generation cephalosporin antibiotics, cefalexin and cefradine, is not associated with induction of simulated Clostridioides difficile infection.

Authors:  Anthony M Buckley; Ines B Moura; James Altringham; Duncan Ewin; Emma Clark; Karen Bentley; Vikki Wilkinson; William Spittal; Georgina Davis; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2021-12-24       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.